Metabolic changes in the plasma of mild Alzheimer’s disease patients treated with Hachimijiogan
暂无分享,去创建一个
Michio Suzuki | K. Ono | S. Hirano | M. Kainuma | M. Murata | D. Sasabayashi | Y. Tsuboi | T. Ohara | S. Shiota | Y. Mori | O. Iritani | Jun-Dal Kim | T. Hamano | K. Wada-isoe | Y. Kajimoto | S. Kawakatsu | K. Funakoshi | Sho Yamasaki | A. Yoshiiwa | S. Ouma | M. Hironishi | M. Yasui | Sotaro Hieda | K. Hayashi | N. Shirafuji | K. Yamashita | Hirohito Sasaki | Hidefumi Ito | Shiro Suda
[1] Michio Suzuki,et al. An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease , 2022, Frontiers in Pharmacology.
[2] T. Ohmori,et al. Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer’s disease (from the Nakayama Study) , 2022, Scientific Reports.
[3] Y. Liu,et al. Activating transcription factor 6 regulates cystathionine to increase autophagy and restore memory in Alzheimer' s disease model mice. , 2022, Biochemical and biophysical research communications.
[4] K. Nagashima,et al. Effectiveness and safety of kamikihito, a traditional Japanese medicine, in managing anxiety among female patients with intractable chronic constipation. , 2021, Complementary therapies in clinical practice.
[5] M. Nagino,et al. Comprehensive metabolome analysis for the pharmacological action of inchinkoto, a hepatoprotective herbal medicine , 2021, Metabolomics.
[6] B. Dunn,et al. Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective. , 2021, JAMA internal medicine.
[7] M. Mintun,et al. Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.
[8] Guowang Xu,et al. Alteration of Metabolic Profile and Potential Biomarkers in the Plasma of Alzheimer’s Disease , 2020, Aging and disease.
[9] Cheng Guo,et al. Association Between Peripheral Adiponectin and Lipids Levels and the Therapeutic Response to Donepezil Treatment in Han Chinese Patients With Alzheimer’s Disease , 2020, Frontiers in Aging Neuroscience.
[10] Fan Wang,et al. High-Throughput Metabolomics for Discovering Potential Biomarkers and Identifying Metabolic Mechanisms in Aging and Alzheimer’s Disease , 2020, Frontiers in Cell and Developmental Biology.
[11] S. Danti,et al. Daily functioning and dementia , 2020, Dementia & neuropsychologia.
[12] D. Bennett,et al. Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis , 2019, Neurobiology of Aging.
[13] H. Lane,et al. D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive impairment , 2019, Pharmacology Biochemistry and Behavior.
[14] D. Hervás,et al. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. , 2019, Journal of proteomics.
[15] Eun Ji Song,et al. Traditional Oriental Medicines and Alzheimer’s Disease , 2019, Aging and disease.
[16] T. Yen,et al. A metabolomic approach to identifying biomarkers in blood of Alzheimer's disease , 2019, Annals of clinical and translational neurology.
[17] A. Nishi,et al. Data on metabolic profiling of healthy human subjects’ plasma before and after administration of the Japanese Kampo medicine maoto , 2018, Data in brief.
[18] R. Suzuki,et al. Change in Amino Acid Pools During Neuronal Differentiation of PC12 Cells , 2018, In Vivo.
[19] David M. Shade,et al. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer’s Disease , 2018, American journal of Alzheimer's disease and other dementias.
[20] H. Nakae,et al. Kampo Medicines for Frailty in Locomotor Disease , 2018, Front. Nutr..
[21] M. Mintun,et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.
[22] J. Wilkins,et al. Application of Metabolomics in Alzheimer’s Disease , 2018, Front. Neurol..
[23] Qiong Yang,et al. Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study , 2017, Alzheimer's & Dementia.
[24] M. Kainuma,et al. The Traditional Japanese Herbal Medicine Hachimijiogan Elicits Neurite Outgrowth Effects in PC12 Cells and Improves Cognitive in AD Model Rats via Phosphorylation of CREB , 2017, Front. Pharmacol..
[25] M. Kainuma,et al. Effect of hachimijiogan on memory impairment induced by beta‐amyloid combined with cerebral ischemia in rats , 2017 .
[26] M. Mielke,et al. Recent advances in the application of metabolomics to Alzheimer's Disease. , 2014, Biochimica et biophysica acta.
[27] Andre Altmann,et al. Sex modifies the APOE‐related risk of developing Alzheimer disease , 2014, Annals of neurology.
[28] H. Soininen,et al. Metabolome in progression to Alzheimer's disease , 2011, Translational Psychiatry.
[29] J. Garcia-Fernández,et al. D‐Aspartic acid is a novel endogenous neurotransmitter , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] G. Fisher,et al. Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients , 2005, Neuroscience Letters.
[31] J. Lindon,et al. Metabonomics: a platform for studying drug toxicity and gene function , 2002, Nature Reviews Drug Discovery.
[32] C. Dolea,et al. World Health Organization , 1949, International Organization.
[33] Kun Xie,et al. High-Throughput Metabolomics for Discovering Potential Biomarkers and Identifying Metabolic Mechanisms in Aging and Alzheimer’s Disease , 2020 .
[34] C. Antunez,et al. A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.